ATF4 and cancer: Apart from the IRE1α axis, the PERK–ATF4–CHOP pathway upregulates explicitly the expression of NKG2DL (mainly MICA and ULBP2) in cancer cells [110], enhancing their binding to NKG2D and subsequently activating NK cells for cancer cell destruction.